Bayer announces results from Phase IV ALTAIR study of two different Treat and Extend (T&E) dosing regimens of aflibercept (Eylea) in patients with wet age-related macular degeneration

The study found that at week 96, up to 60% of patients were able to receive three-monthly or more injections, with more than 40% able to receive four-monthly injections. This represents potential to relieve capacity pressures and treatment costs for NHS.

SPS commentary:

The current licensed dosing regimen is one injection per month for three consecutive doses. The treatment interval is then extended to two months. Based on the physician's judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at two months or further extended using a treat-and-extend dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly to a minimum of two months during the first 12 months of treatment.

There is no requirement for monitoring between injections.